NO20005081L - A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof - Google Patents
A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereofInfo
- Publication number
- NO20005081L NO20005081L NO20005081A NO20005081A NO20005081L NO 20005081 L NO20005081 L NO 20005081L NO 20005081 A NO20005081 A NO 20005081A NO 20005081 A NO20005081 A NO 20005081A NO 20005081 L NO20005081 L NO 20005081L
- Authority
- NO
- Norway
- Prior art keywords
- amino acid
- polypeptide
- binding protein
- choline binding
- acid sequence
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 101710164918 Choline-binding protein Proteins 0.000 title abstract 6
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 102000004856 Lectins Human genes 0.000 abstract 1
- 108090001090 Lectins Proteins 0.000 abstract 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract 1
- 229960001231 choline Drugs 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000002523 lectin Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oppfinnelsen frembringer et isolert polypeptid som omfatter en aminosyresekvens av et N-terminalt kolinbindende protein A trunkat hvori aminosyresekvensen er fremlagt i en. av SEQ ID NOS: 1, 3-7, eller 9-11, inklusive fragmenter, mutanter, varianter, analoger eller derivater derav. Videre frembringer denne oppfinnelse isolerte polypeptider som omfatter en aminosyresekvens av et N-terminalt kolinbindende protein A trunkat, hvori aminosyren er fremlagt i SEQ ID NO 24, hvori polypeptidet beholder sin opprinnelige tertiære struktur og fremgangsmåter til fremstilling. Denne oppfinnelse frembringer et". isolert polypeptid som omfatter en aminosyresekvens av et N-terminalt kolinbindende protein A trunkat, hvori polypeptidet har lektinaktivitet og ikke bindes til kolinet. Oppfinnelsen frembringer et isolert immunogent polypeptid som omfatter en aminosyresekvens for et N-terminalt kolinbindende protein A trunkat. Oppfinnelsen frembringer en isolert nukleinsyre som koder for et polypeptid som omfatter en aminosyresekvens for N-terminalt kolinbindende protein A trunkat. Endelig frembringer denne oppfinnelse farmasøytiske preparater, vaksiner og diagnostiske og terapeutiske fremgangsmåter til anvendelse.The invention provides an isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A truncate wherein the amino acid sequence is presented in a. of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs or derivatives thereof. Furthermore, this invention provides isolated polypeptides comprising an amino acid sequence of an N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO 24, wherein the polypeptide retains its original tertiary structure and methods of preparation. This invention provides an "isolated polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A trunkate, wherein the polypeptide has lectin activity and does not bind to the choline. The invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of an N-terminal choline binding protein A The invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of N-terminal choline binding protein A. truncate Finally, this invention provides pharmaceutical compositions, vaccines and diagnostic and therapeutic methods for use.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8087898P | 1998-04-07 | 1998-04-07 | |
| US09/056,019 US6858706B2 (en) | 1998-04-07 | 1998-04-07 | Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
| PCT/US1999/007669 WO1999051188A2 (en) | 1998-04-07 | 1999-04-07 | A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005081D0 NO20005081D0 (en) | 2000-10-09 |
| NO20005081L true NO20005081L (en) | 2000-12-06 |
Family
ID=26734874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005081A NO20005081L (en) | 1998-04-07 | 2000-10-09 | A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JP4739521B2 (en) |
| KR (1) | KR100638503B1 (en) |
| CN (1) | CN1191851C (en) |
| AU (2) | AU3479699A (en) |
| BR (1) | BR9909910A (en) |
| CA (1) | CA2326388C (en) |
| HU (1) | HUP0102306A3 (en) |
| IL (1) | IL138939A0 (en) |
| MX (1) | MXPA00009899A (en) |
| NO (1) | NO20005081L (en) |
| NZ (1) | NZ507983A (en) |
| PL (1) | PL193132B1 (en) |
| TR (1) | TR200003498T2 (en) |
| WO (1) | WO1999051188A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
| CA2808919C (en) | 2005-12-22 | 2016-04-19 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae capsular saccharide vaccine |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| EP2687228B1 (en) | 2007-06-26 | 2017-07-19 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| KR20110009157A (en) | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccine |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| US20140072622A1 (en) | 2011-05-17 | 2014-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6592876B1 (en) * | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
| ATE323721T1 (en) * | 1996-05-01 | 2006-05-15 | Univ Rockefeller | CHOLINE-BINDING PROTEIN USED AS AN PNEUMOCOCCAL VACCINE |
| EP0941335A2 (en) * | 1996-10-31 | 1999-09-15 | Human Genome Sciences | Streptococcus pneumoniae polynucleotides and sequences |
| US6291654B1 (en) * | 1996-11-12 | 2001-09-18 | Regents Of The University Of Minnesota | Method for isolating a C3 binding protein of streptococcus pneumoniae |
| US6858706B2 (en) * | 1998-04-07 | 2005-02-22 | St. Jude Children's Research Hospital | Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
| EP1067962B1 (en) * | 1998-04-07 | 2010-03-24 | MedImmune, LLC | Derivatives of pneumococcal choline binding proteins for vaccines |
-
1999
- 1999-04-07 TR TR2000/03498T patent/TR200003498T2/en unknown
- 1999-04-07 MX MXPA00009899A patent/MXPA00009899A/en unknown
- 1999-04-07 KR KR1020007011206A patent/KR100638503B1/en not_active IP Right Cessation
- 1999-04-07 WO PCT/US1999/007669 patent/WO1999051188A2/en active IP Right Grant
- 1999-04-07 AU AU34796/99A patent/AU3479699A/en not_active Withdrawn
- 1999-04-07 PL PL347946A patent/PL193132B1/en unknown
- 1999-04-07 CN CNB998108545A patent/CN1191851C/en not_active Expired - Fee Related
- 1999-04-07 IL IL13893999A patent/IL138939A0/en unknown
- 1999-04-07 AU AU34797/99A patent/AU764811B2/en not_active Ceased
- 1999-04-07 JP JP2000541960A patent/JP4739521B2/en not_active Expired - Fee Related
- 1999-04-07 BR BR9909910-1A patent/BR9909910A/en not_active Application Discontinuation
- 1999-04-07 CA CA2326388A patent/CA2326388C/en not_active Expired - Fee Related
- 1999-04-07 HU HU0102306A patent/HUP0102306A3/en unknown
- 1999-04-07 NZ NZ507983A patent/NZ507983A/en not_active IP Right Cessation
-
2000
- 2000-10-09 NO NO20005081A patent/NO20005081L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010052244A (en) | 2001-06-25 |
| WO1999051188A2 (en) | 1999-10-14 |
| TR200003498T2 (en) | 2001-10-22 |
| CA2326388C (en) | 2014-02-04 |
| NZ507983A (en) | 2004-03-26 |
| AU3479699A (en) | 1999-10-25 |
| CA2326388A1 (en) | 1999-10-14 |
| KR100638503B1 (en) | 2006-10-26 |
| CN1342088A (en) | 2002-03-27 |
| BR9909910A (en) | 2002-01-15 |
| JP2002516662A (en) | 2002-06-11 |
| AU3479799A (en) | 1999-10-25 |
| PL193132B1 (en) | 2007-01-31 |
| HUP0102306A3 (en) | 2008-04-28 |
| MXPA00009899A (en) | 2002-05-08 |
| WO1999051188A9 (en) | 2000-10-12 |
| IL138939A0 (en) | 2001-11-25 |
| NO20005081D0 (en) | 2000-10-09 |
| AU764811B2 (en) | 2003-08-28 |
| HUP0102306A1 (en) | 2001-09-28 |
| JP4739521B2 (en) | 2011-08-03 |
| CN1191851C (en) | 2005-03-09 |
| PL347946A1 (en) | 2002-04-22 |
| WO1999051188A3 (en) | 2001-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019210579B2 (en) | RSV F protein mutants | |
| KR102482994B1 (en) | Vaccine composition for preventing or treating infection of SARS-CoV-2 | |
| EP4163291A1 (en) | Polypeptide vaccine coupled with tlr7 agonist for novel coronavirus and use thereof | |
| Liu et al. | Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates | |
| CN102066410A (en) | HLA-DR binding peptides and their uses | |
| Solioz et al. | The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis | |
| PT754231E (en) | Peptide fragment of the respiratory syncytial virus g protein, immunogenic agent, pharmaceutical composition containing same, and preparation method | |
| CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| EP2118128B1 (en) | Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1 | |
| US20230338510A1 (en) | Novel coronavirus tandem epitope polypeptide vaccine and use thereof | |
| Davis et al. | Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin | |
| JP2019013229A (en) | CyaA-BASED CHIMERIC PROTEINS COMPRISING HETEROLOGOUS POLYPEPTIDE AND THEIR USES IN INDUCTION OF IMMUNE RESPONSES | |
| NO20005081L (en) | A polypeptide comprising the amino acid of an N-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof | |
| US8309096B2 (en) | Fusion protein | |
| US7862828B2 (en) | Allergy vaccines containing hybrid polypeptides | |
| EP0815136A1 (en) | Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm) | |
| WO2023138333A1 (en) | Recombinant sars-cov-2 protein vaccine, and preparation method therefor and use thereof | |
| KR102369146B1 (en) | Formulation of Corona virus vaccine | |
| US20230192777A1 (en) | Epitopic vaccine for african swine fever virus | |
| KR20220056817A (en) | Vaccine composition for preventing or treating infection of SARS-CoV-2 | |
| CN114621329A (en) | T cell epitope peptide compound | |
| CN100408595C (en) | SARS virus HLA-A2 limited epitope polypeptide and uses thereof | |
| CA3076263C (en) | Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv) | |
| WO2003022867A3 (en) | Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag | |
| WO2023117742A1 (en) | Vaccine compositions and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application | ||
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |